These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 11840416)
1. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Hansen SW Semin Oncol; 2002 Feb; 29(1 Suppl 1):17-9. PubMed ID: 11840416 [TBL] [Abstract][Full Text] [Related]
2. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178 [TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA; Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine in the treatment of ovarian cancer. Hansen SW Int J Gynecol Cancer; 2001; 11 Suppl 1():39-41. PubMed ID: 11489002 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Kose MF; Meydanli MM; Tulunay G Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860 [TBL] [Abstract][Full Text] [Related]
6. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132 [TBL] [Abstract][Full Text] [Related]
8. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Thigpen T Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800 [TBL] [Abstract][Full Text] [Related]
9. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Thigpen T Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415 [TBL] [Abstract][Full Text] [Related]
10. Current and future perspectives in advanced bladder cancer: is there a new standard? von der Maase H Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002 [TBL] [Abstract][Full Text] [Related]
12. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Bookman MA Semin Oncol; 2002 Feb; 29(1 Suppl 1):20-31. PubMed ID: 11840417 [TBL] [Abstract][Full Text] [Related]
13. Future directions in the chemotherapy of ovarian cancer. Ozols RF Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230 [TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer. Gupta SK; John S; Naik R; Arora R; Selvamani B; Fuloria J; Ganesh N; Awasthy BS Gynecol Oncol; 2005 Jul; 98(1):134-40. PubMed ID: 15894360 [TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
16. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in the treatment of ovarian cancer. Hansen SW; Tuxen MK; Sessa C Ann Oncol; 1999; 10 Suppl 1():51-3. PubMed ID: 10219453 [TBL] [Abstract][Full Text] [Related]